Table 1. Comparison of ligand activation of wildtype and mutant mTRPV1 channels by capaicin analogs.

	Cap			Cap-1			Cap+1
	EC50 (µM)	K	N	EC50 (µM)	K	N	EC50 (µM)	K	N
WT	0.14 ± 0.01	1.82 ± 0.22	4	0.10 ± 0.01	1.20 ± 0.05	3	4.31 ± 0.23*	1.44 ± 0.11	4
T551V	1.56 ± 0.20†	1.74 ± 0.13	5	9.13 ± 1.10*‡	1.83 ± 0.31	5	70.12 ± 7.74*§	1.71 ± 0.10	8
E571A	1.53 ± 0.10†	1.86 ± 0.07	4	19.31 ± 0.22*‡	2.01 ± 0.02	6	31.43 ± 0.02*§	1.84 ± 0.11	6
I574A	0.22 ± 0.02†	1.41 ± 0.12	3	2.80 ± 0.11*‡	1.35 ± 0.23	7	10.73 ± 0.33*§	1.98 ± 0.12	5
T671S	0.05 ± 0.06	0.87 ± 0.11	3	22.80 ± 0.40*‡	4.94 ± 0.30	3	35.29 ± 1.19*§	3.16 ± 0.45	3
Y512F	1.12 ± 0.17†	1.35 ± 0.08	4	25.18 ± 1.18*‡	2.68 ± 0.34	3	99.48 ± 6.82*§	1.46 ± 0.17	3

^* Compared to Capsaicin (Cap).

^†Compared to WT Cap.

^‡Compared to WT Cap_-1.

^§Compared to WT Cap₊₁.

EC₅₀, half maximal effective concentration; K, Hill coefficient; N, number of patches.